Vlad C. Vasile, M.D., Ph.D.

  1. Cardiologist
  1. Manzato M, Meeusen JW, Donato LJ, Jaffe AS, Vasile VC. Lipoprotein (a) testing patterns among subjects with a measured lipid panel: The Mayo Clinic experience. Am J Prev Cardiol. 2024 Dec; 20:100886 Epub 2024 Oct 18
    View PubMed
  2. Churchill RA, Gochanour BR, Scott CG, Vasile VC, Rodeheffer RJ, Meeusen JW, Jaffe AS. Association of cardiac biomarkers with long-term cardiovascular events in a community cohort. Biomarkers. 2024 Jun; 29 (4):161-170 Epub 2024 Apr 26
    View PubMed
  3. Khan D, Elhadi M, Vasile VC. 59-Year-Old Woman With Episodic Chest Pain. Mayo Clin Proc. 2024 Jan; 99 (1):146-152
    View PubMed
  4. Akhiyat N, Vasile V, Ahmad A, Sara JD, Nardi V, Lerman LO, Jaffe A, Lerman A. Plasma Ceramide Levels Are Elevated in Patients With Early Coronary Atherosclerosis and Endothelial Dysfunction. J Am Heart Assoc. 2022 Apr 5; 11 (7):e022852 Epub 2022 Mar 18
    View PubMed
  5. Sharain K, Vasile VC, Sandoval Y, Donato LJ, Clements CM, Newman JS, Karon BS, Jaffe AS. The Elevated High-Sensitivity Cardiac Troponin T Pilot: Diagnoses and Outcomes. Mayo Clin Proc. 2021 Sep; 96 (9):2366-2375 Epub 2021 May 13
    View PubMed
  6. Vasile VC, Meeusen JW, Medina Inojosa JR, Donato LJ, Scott CG, Hyun MS, Vinciguerra M, Rodeheffer RR, Lopez-Jimenez F, Jaffe AS. Ceramide Scores Predict Cardiovascular Risk in the Community. Arterioscler Thromb Vasc Biol. 2021 Apr; 41 (4):1558-1569 Epub 2021 Feb 18
    View PubMed
  7. Fatica EM, Meeusen JW, Vasile VC, Jaffe AS, Donato LJ. Corrigendum to "Measuring the contribution of Lp(a) cholesterol towards LDL-C interpretation" [Clin. Biochem. 86 (2020) 45-51]. Clin Biochem. 2021 Feb; 88:56-57 Epub 2021 Jan 19
    View PubMed
  8. Buciuc M, Vasile VC, Conte GM, Scharf EL. Ceramide Dynamics and Prognostic Value in Acute and Subacute Ischemic Stroke: Preliminary Findings in a Clinical Cohort Journal of Neurology Research. 2020; 10(6):209-219.
  9. Meeusen JW, Donato LJ, Kopecky SL, Vasile VC, Jaffe AS, Laaksonen R. Ceramides improve atherosclerotic cardiovascular disease risk assessment beyond standard risk factors. Clin Chim Acta. 2020 Dec; 511:138-142 Epub 2020 Oct 12
    View PubMed
  10. Fatica EM, Meeusen JW, Vasile VC, Jaffe AS, Donato LJ. Measuring the contribution of Lp(a) cholesterol towards LDL-C interpretation. Clin Biochem. 2020 Dec; 86:45-51 Epub 2020 Sept 28
    View PubMed
  11. Hilvo M, Vasile VC, Donato LJ, Hurme R, Laaksonen R. Ceramides and Ceramide Scores: Clinical Applications for Cardiometabolic Risk Stratification. Front Endocrinol (Lausanne). 2020; 11:570628 Epub 2020 Sept 29
    View PubMed
  12. Van SL, Vasile VC, Ommen SR, Will ML, Tajik AJ, Gersh BJ, Ackerman MJ. Van Driest SL, Vasile VC, Ommen SR, Will ML, Tajik AJ, Gersh BJ, Ackerman MJ. Myosin binding protein C mutations and compound heterozygosity in hypertrophic cardiomyopathy JACC. 2019.
    View PubMed
  13. Ravichandran J, Woon SY, Quek YS, Lim YC, Noor EM, Suresh K, Vigneswaran R, Vasile V, Shah A, Mills NL, Sickan J, Beshiri A, Jaffe AS. High-Sensitivity Cardiac Troponin I Levels in Normal and Hypertensive Pregnancy. Am J Med. 2019 Mar; 132 (3):362-366 Epub 2018 Nov 30
    View PubMed
  14. Vasile VC, Jaffe AS. High-sensitivity cardiac troponin in the evaluation of possible AMI JACC. 2018; http//www.acc.org((Expert Analysis)):2018.
  15. Sharain K, Vasile VC, Jaffe AS. Does cardiac rhythm monitoring in patients with elevated troponin levels lead to changes in management? Eur Heart J Acute Cardiovasc Care. 2017 Sep; 6 (6):545-552 Epub 2016 Jan 27
    View PubMed
  16. Vasile VC, Jaffe AS. High-Sensitivity Cardiac Troponin for the Diagnosis of Patients with Acute Coronary Syndromes. Curr Cardiol Rep. 2017 Aug 24; 19 (10):92
    View PubMed
  17. Vasile VC, Jaffe AS. Natriuretic Peptides and Analytical Barriers. Clin Chem. 2017 Jan; 63 (1):50-58 Epub 2016 Oct 10
    View PubMed
  18. Vasile VC, Jaffe AS. Emerging biomarkers for acute heart conditions. Curr Opin Cardiol. 2014 Jul; 29 (4):312-8
    View PubMed
  19. Vasile VC, Chai HS, Abdeldayem D, Afessa B, Jaffe AS. Elevated cardiac troponin T levels in critically ill patients with sepsis. Am J Med. 2013 Dec; 126 (12):1114-21 Epub 2013 Sept 28
    View PubMed
  20. Jaffe AS, Vasile VC, Milone M, Saenger AK, Olson KN, Apple FS. Diseased skeletal muscle: a noncardiac source of increased circulating concentrations of cardiac troponin T. J Am Coll Cardiol. 2011 Oct 18; 58 (17):1819-24 Epub 2011 Sept 29
    View PubMed
  21. Vasile VC, Chai HS, Khambatta S, Afessa B, Jaffe AS. Significance of elevated cardiac troponin T levels in critically ill patients with acute respiratory disease. Am J Med. 2010 Nov; 123 (11):1049-58
    View PubMed
  22. Vasile VC, Saenger AK, Kroning JM, Jaffe AS. Biological and analytical variability of a novel high-sensitivity cardiac troponin T assay. Clin Chem. 2010 Jul; 56 (7):1086-90 Epub 2010 May 14
    View PubMed
  23. Vasile VC, Babuin L, Ting HH, Bell MR, Orme NM, Yuan BY, Perez JA, Alegria JR, Bellolio F, Haro LH, Jaffe AS. Aborted myocardial infarction: is it real in the troponin era? Am Heart J. 2009 Apr; 157 (4):636-41 Epub 2009 Jan 31
    View PubMed
  24. Vasile VC, Blauwet LA, Jaffe AS. Serial determination of troponin concentrations in the diagnosis of acute myocardial infarction. Heart and Metabolism. 2009; (43):27-9.
  25. Vasile VC, Jaffe AS. The biological basis of troponin in heart disease: Possible uses for troponin fragmentology. Heart Metab. 2009(43):5-8.
  26. Vasile VC, Babuin L, Rio Perez JA, Alegria JR, Song LM, Chai HS, Afessa B, Jaffe AS. Long-term prognostic significance of elevated cardiac troponin levels in critically ill patients with acute gastrointestinal bleeding. Crit Care Med. 2009 Jan; 37(1):140-7.
    View PubMed
  27. Babuin L, Vasile VC, Rio Perez JA, Alegria JR, Chai HS, Afessa B, Jaffe AS. Elevated cardiac troponin is an independent risk factor for short- and long-term mortality in medical intensive care unit patients. Crit Care Med. 2008 Mar; 36(3):759-65.
    View PubMed
  28. Vasile VC, Jaffe AS. New potential uses for cardiac troponins. Biomark Med. 2007 Dec; 1(4):491-501.
    View PubMed
  29. Rajamannan NM, Subramaniam M, Abraham TP, Vasile VC, Ackerman MJ, Monroe DG, Chew TL, Spelsberg TC. TGFbeta inducible early gene-1 (TIEG1) and cardiac hypertrophy: Discovery and characterization of a novel signaling pathway. J Cell Biochem. 2007 Feb 1; 100(2):315-25.
    View PubMed
  30. Vasile VC, Edwards WD, Ommen SR, Ackerman MJ. Obstructive hypertrophic cardiomyopathy is associated with reduced expression of vinculin in the intercalated disc. Biochem Biophys Res Commun. 2006 Oct 20; 349 (2):709-15 Epub 2006 Aug 24
    View PubMed
  31. Vasile VC, Ommen SR, Edwards WD, Ackerman MJ. A missense mutation in a ubiquitously expressed protein, vinculin, confers susceptibility to hypertrophic cardiomyopathy. Biochem Biophys Res Commun. 2006 Jul 7; 345(3):998-1003. Epub 2006 May 04.
    View PubMed
  32. Vasile VC, Will ML, Ommen SR, Edwards WD, Olson TM, Ackerman MJ. Identification of a metavinculin missense mutation, R975W, associated with both hypertrophic and dilated cardiomyopathy. Mol Genet Metab. 2006 Feb; 87 (2):169-74 Epub 2005 Oct 19
    View PubMed
  33. Goetz MP, Toft D, Reid J, Ames M, Stensgard B, Safgren S, Adjei AA, Sloan J, Atherton P, Vasile V, Salazaar S, Adjei A, Croghan G, Erlichman C. Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer. J Clin Oncol. 2005 Feb 20; 23(6):1078-87.
    View PubMed
  34. Van Driest SL, Vasile VC, Ommen SR, Will ML, Tajik AJ, Gersh BJ, Ackerman MJ. Myosin binding protein C mutations and compound heterozygosity in hypertrophic cardiomyopathy. J Am Coll Cardiol. 2004 Nov 2; 44 (9):1903-10
    View PubMed
  35. Van SL, Vasile VC, Ommen SR, Will ML, Tajik AJ, Gersh BJ, Ackerman MJ. Van Driest SL, Vasile VC, Ommen SR, Will ML, Tajik AJ, Gersh BJ, Ackerman MJ. Myosin binding protein C mutations and compound heterozygosity in hypertrophic cardiomyopathy JACC. 2004.
    View PubMed
  36. D'Assoro AB, Busby R, Suino K, Delva E, Almodovar-Mercado GJ, Johnson H, Folk C, Farrugia DJ, Vasile V, Stivala F, Salisbury JL. Genotoxic stress leads to centrosome amplification in breast cancer cell lines that have an inactive G1/S cell cycle checkpoint. Oncogene. 2004 May 20; 23(23):4068-75.
    View PubMed